Treatment Details – 29.2 months
|Patients: This Phase II study involved 17 patients with Malignant Pleural Mesothelioma. Many of the patients had undergone “preventive radiotherapy.”|
Treatment: The treatment consisted of a type of immunotherapy – administration of intrapleurally infused autologous human activated macrophages (a type of blood cell) followed by intrapleural injection of gamma-interferon (a type of protein). After completion of this therapy, ten patients were treated with chemotherapy (primarily cisplatin (platinol) and mitomycin (mitozytrex)).
Toxicity: Toxicities included grade 2 or 3 thoracic pain after injection, fever, and alkaline phosphatases.
Results: The median survival of all treated patients was 29.2 months.
Correspondence: Manuel Lopez, MD